ALTSTATION.IO

Merck & Co., Inc. (MRK) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$121.45

Change

+1.42%

Market Cap

$303.36B

Avg Volume

14.7M

Company Overview

Merck & Co., Inc. is a global healthcare company based in Rahway, New Jersey. They focus on human and veterinary pharmaceuticals, offering a wide range of products such as Keytruda for cancer treatment, Gardasil for HPV prevention, and vaccines for various diseases. Their customer base includes hospitals, clinics, and veterinarians, providing health solutions for both humans and animals.

In terms of market position, Merck is a leader in the pharmaceutical sector, especially in oncology and vaccines. They have a strong portfolio of blockbuster drugs, with Keytruda alone generating over $18 billion in revenue in 2022. However, they face competition from companies like Pfizer and Bristol-Myers Squibb, especially in the oncology space. The patent expirations of some key products pose a threat, but their robust development pipeline helps mitigate this risk.

Currently, Merck is experiencing growth, driven by strong sales from Keytruda and its expanding vaccine offerings. The company has been making strategic partnerships to enhance its oncology portfolio, including collaborations with AstraZeneca and Daiichi Sankyo for cancer therapies. Recent milestones include the launch of new vaccines and treatments, indicating that Merck is not only sustaining its market position but also actively pursuing innovations to drive future growth.

Key Financials

Market Cap

$303.36B

Revenue

$65.01B

EBITDA

$28.80B

Gross Margin

77.1%

Profit Margin

28.1%

Revenue Growth

5.0%

Total Cash

$18.21B

Total Debt

$41.37B

Free Cash Flow

N/A

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

16.68

Forward P/E

12.35

Beta

0.30

52-Week High

$122.66

52-Week Low

$73.31

EPS

$7.28

50-Day Avg

$106.03

200-Day Avg

$88.62

Price/Book

5.83

Technical Analysis

Over the past 52 weeks, Merck & Co., Inc. (MRK) has exhibited a strong upward trend, climbing from a low around $70 to its current price of $121.45, representing a 46.4% increase. Key support is evident at the $80 level, where the price stabilized during June, while resistance is observed around $122, near the current range. The chart displays a series of higher highs and higher lows, particularly from November onwards, implying a bull trend, alongside a potential ascending triangle pattern forming as it approaches the resistance at $122. In recent weeks, MRK has shown positive momentum, rallying sharply after consolidating around the $115 level in late January. Presently, at $121.45, the price is just below the 52-week high of $121.93, indicating strong bullish sentiment and potential for breakout above that resistance level.

Recent News and Developments

Here’s a summary of the latest news and developments for Merck & Co., Inc

(MRK) stock in the past week:

Market Update

### Merck Reports Strong Q4 2025 Earnings but Offers Cautious 2026 Outlook

Market Update

Merck announced its fourth-quarter and full-year 2025 financial results on February 3, 2026, reporting adjusted earnings per share (EPS) of $2.04, surpassing the consensus estimate of $2.01. The company’s revenue for the quarter also exceeded expectations at $16.40 billion, a 5.0% increase year-over-year. Despite the strong Q4 performance, Merck’s shares declined by approximately 3% in premarket t

Market Sentiment and Analyst Recommendations

Bull Case

Merck crushed Q4 earnings with revenue at $16.40B (5.0% YoY growth) and beat EPS estimates, proving operational execution is solid. The stock has rallied 46.4% over 52 weeks and sits at $121.45 with 26 analysts rating it a buy, suggesting institutional conviction remains intact. WINREVAIR just got European Commission approval for expanded PAH indications and has an FDA decision coming September 21, 2026—this pipeline momentum could drive significant revenue upside beyond current guidance. At a P/E of 16.68, Merck trades at a reasonable multiple for a pharma giant with $65.01B in annual revenue and $18.21B in cash. The stock is forming a potential ascending triangle near resistance at $122, and technical momentum suggests a breakout is plausible if the company executes on its 2026 targets.

Bear Case

The 2026 guidance of $5.00-$5.15 EPS missed Wall Street’s $5.63 estimate by roughly 10%, triggering a 3% premarket selloff and signaling management expects headwinds ahead. The Cidara acquisition carries a $3.65 per share one-time charge that masks underlying earnings power and raises questions about integration risk and capital allocation judgment. Merck carries $41.37B in total debt against $18.21B in cash, leaving a net debt position of $23.16B that limits financial flexibility if revenue growth slows or R&D investments disappoint. The 5.0% revenue growth is pedestrian for a company of this scale and suggests the patent cliff is real—blockbuster drugs are aging and new pipeline winners haven’t yet offset losses. At $121.45, the stock has already run 46.4% in 52 weeks and sits just below the 52-week high, leaving limited margin of safety if guidance misses again or macro conditions tighten.

What to Watch

Monitor the September 21, 2026 FDA decision on WINREVAIR label expansion closely—approval would validate the PAH franchise expansion thesis and likely drive a 3-5% stock pop. Track Q1 2026 revenue and organic growth rates (excluding Cidara) to confirm whether the 5.0% growth trajectory holds or accelerates; anything below 4% would signal pipeline issues. Watch for any updates on key patent expirations and competitive threats from generics or biosimilars, particularly for legacy franchises that still drive meaningful revenue. The debt-to-equity ratio and free cash flow conversion matter—if cash generation weakens or debt creeps higher, the dividend safety comes into question and could trigger downgrades. Finally, monitor analyst estimate revisions over the next two quarters; if the Street starts cutting 2027-2028 guidance, it signals the market is losing confidence in long-term growth despite near-term beats.

Analyst Consensus

BUY

Based on 26 analyst opinions

Low Target

$86.00

Mean Target

$121.27

High Target

$140.00

Earnings and Financial Data

Sector

Healthcare

Industry

Drug Manufacturers – General

Employees

N/A

Earnings & Dividends

Next Earnings

Apr 30, 2026

EPS (Trailing)

$7.28

Dividend Yield

284.0%

Payout Ratio

45.0%

Frequently Asked Questions

Is MRK a good stock to buy?

Yes, analysts recommend a BUY on Merck & Co. with a target price of $121.27. Given its solid fundamentals and P/E ratio of 16.68, MRK appears to be a strong investment in the healthcare sector.

What is MRK’s price target?

The analyst consensus sets MRK’s price target at $121.27. This is slightly below the current price of $121.45, indicating potential for modest gains.

Does MRK pay a dividend?

Yes, MRK offers a dividend yield of 2.84%. This makes it an attractive option for income-focused investors looking for reliable returns in the healthcare space.

What is the 52-week range for MRK?

The 52-week range for MRK is $73.31 to $122.66. Currently trading near its high, this reflects strong market performance and investor confidence.

How does MRK’s forward P/E compare to its current P/E?

MRK’s current P/E is 16.68, while the forward P/E is significantly lower at 12.35. This suggests potential for earnings growth and may indicate that MRK is undervalued at its current price.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.